DS
LGND icon

David Shaw’s Ligand Pharmaceuticals LGND Stock Holding History

David Shaw’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Buy
8,200
+1,600
+24% +$377K ﹤0.01% 2978
2026
Q1 		$1.32M Sell
6,600
-1,000
-13% -$198K ﹤0.01% 3231
2025
Q4 		$1.44M Buy
7,600
+6,000
+375% +$1.15M ﹤0.01% 3296
2025
Q3 		$283K Buy
+1,600
New +$238K ﹤0.01% 4140
2021
Q3 		– Sell
-16,030
Closed -$1.31M – 5092
2021
Q2 		$1.31M Hold
16,030
– – ﹤0.01% 3324
2021
Q1 		$1.52M Buy
+16,030
New +$1.52M ﹤0.01% 2806
2019
Q4 		– Sell
-58,510
Closed -$3.63M – 4072
2019
Q3 		$3.63M Sell
58,510
-32,060
-35% -$2.01M ﹤0.01% 1882
2019
Q2 		$6.45M Buy
90,570
+82,876
+1,077% +$6.1M 0.01% 1423
2019
Q1 		$603K Sell
7,694
-11,061
-59% -$838K ﹤0.01% 2898
2018
Q4 		$1.59M Sell
18,755
-28,373
-60% -$3.02M ﹤0.01% 2345
2018
Q3 		$8.07M Buy
47,128
+18,755
+66% +$2.83M 0.01% 1239
2018
Q2 		$3.67M Buy
28,373
+12,343
+77% +$1.38M ﹤0.01% 1753
2018
Q1 		$1.65M Hold
16,030
– – ﹤0.01% 2175
2017
Q4 		$1.37M Buy
+16,030
New +$1.39M ﹤0.01% 2391
2017
Q1 		– Sell
-16,030
Closed -$1.02M – 3457
2016
Q4 		$1.02M Buy
+16,030
New +$1.01M ﹤0.01% 2449
2016
Q1 		– Sell
-9,939
Closed -$672K – 3625
2015
Q4 		$672K Hold
9,939
– – ﹤0.01% 2896
2015
Q3 		$531K Buy
+9,939
New +$603K ﹤0.01% 3022
2014
Q3 		– Sell
-16,030
Closed -$623K – 4257
2014
Q2 		$623K Sell
16,030
-42,319
-73% -$1.72M ﹤0.01% 3340
2014
Q1 		$2.45M Buy
58,349
+49,372
+550% +$2.06M ﹤0.01% 2188
2013
Q4 		$295K Sell
8,977
-33,342
-79% -$1.09M ﹤0.01% 4068
2013
Q3 		$1.14M Sell
42,319
-13,946
-25% -$392K ﹤0.01% 2909
2013
Q2 		$1.31M Buy
+56,265
New +$1.01M ﹤0.01% 2486

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's LGND Position: Q2 2026 in Review

David Shaw reduced its Ligand Pharmaceuticals (LGND) stake by 28% in Q2 2026, selling an estimated $5.16M and leaving 56,515 shares worth $17.9M. The position accounts for 0.01% of the portfolio, ranked #1361.

David Shaw first reported a position in LGND in Q2 2013 and has held it in 37 quarters since. The position peaked at $22.9M in Q4 2018. 413 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • David Shaw held 56,515 shares of Ligand Pharmaceuticals worth $17.9M as of Q2 2026.
  • David Shaw sold 21,913 Ligand Pharmaceuticals shares in Q2 2026, an estimated $5.16M.
  • Ligand Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1361 holding.
  • David Shaw first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
  • David Shaw's Ligand Pharmaceuticals position peaked at $22.9M in Q4 2018.
  • 413 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.